Heart failure also involves the development of vascular inflammation, and the sodium-glucose cotransporter 2 (SGLT2) inhibitor Canagliflozin (Cana) can reduce inflammation in endothelial cells via HK2 reductions, revealing that Cana has a novel anti-inflammatory mechanism via HK2 [53]. Here, HK2 is linked to heart failure.